TY  - JOUR
VL  - 36
UR  - http://doi.org/10.1093/humrep/deaa359
SN  - 0268-1161
Y1  - 2020/12//
N2  - Sir,

In their recently published study, Yaron et al. (2020) expose an interesting strategy based in cfDNA testing (cfDNA-T) which could serve as an alternative to cytogenetic analysis in products of conceptions in recurrent pregnancy loss and could guide further management of this medical topic; however, in our opinion, some important aspects should be considered.

Firstly, Illanes et al. (2007) found that cfDNA concentration in the maternal blood can be detected from Week 4 of gestation but it is only reliable from Week 7. However, others authors? experience could be different. Clark-Ganheart et al. (2015) recommend cfDNA analysis only after 8?weeks of gestation. Zeevi et al. (2018) reported that aneuploidy screening by cfDNA is not generally accurate before Week 8, leading to a period in pregnancy (namely, Weeks 4 through 8) during which assessment of the genetic status of the embryo is not generally feasible. Galeva et al....
JF  - Human Reproduction
SP  - 827
IS  - 3
A1  - Marcos Rodríguez, Ana Teresa
A1  - Navarro-Pando, José Manuel
AV  - none
TI  - Letter: cfDNA testing in recurrent pregnancy loss: a new step in the right way but still raw for the clinical area
EP  - 829
ID  - uneatlantico510
ER  -